Verona Pharma PLC ADR (VRNA NASDAQ) stock market data APIs
$65.7897
3.32(5%)
as of May 8, 2025
Verona Pharma PLC ADR Financial Data Overview
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Prev. Close
65.7897
Open
69.1078
High
69.7409
Low
64.1623
52 wk Range
11.39-74.18
Market Cap
9 689 M
Shares Outstanding
85 132 K
Revenue
119 M
EPS
-0.02
Beta
0.205
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Verona Pharma PLC ADR data using free add-ons & libraries
Get Verona Pharma PLC ADR Fundamental Data
Verona Pharma PLC ADR Fundamental data includes:
- Net Revenue: 119 M
- EBITDA: -133 641 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-25
- EPS/Forecast: -0.0325
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Verona Pharma PLC ADR News
New
What Makes Verona Pharma plc (VRNA) a Good Investment?
Buckley Capital Advisors, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned -0.5% (net) in the quarter c...
IBD Stock Of The Day Verona Pharma Tests Buy Point After Earnings Breakout
Tuesday's Stock Of The Day is testing a buy point after Verona Pharma broke out last week on blowout sales for its COPD treatment. Continue Reading View Comments
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025
Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Ver...
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025
Verona Pharma plc Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
